FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2583115655> ?p ?o ?g. }

• W2583115655 abstract "Abstract INTRODUCTION: Impaired renal function in patients with multiple myeloma (MM) is associated with adverse clinical outcome. Historically, the renal status is reported as serum creatinine (SCr) only. Introduction of novel agents (thalidomide, lenalidomide, bortezomib and pegylated liposomal doxorubicin) in MM therapeutics has improved clinical responses and overall survival. An important question that remains largely unanswered is if these agents deliver equal benefit to patients with impaired renal function. Thus we investigate the overall benefit of novel agents in MM patients with renal impairment. METHODS: All MM patients treated between January 2000 and December 2007 at Roswell Park Cancer Institute (RPCI) where included in this analysis. Extent of disease was assessed based on the Durie-Salmon staging system. We determined glomerular filtration rate (GFR) to asses renal function more accurately. GFR was calculated utilizing the Modification of Diet in Renal Disease (MDRD) equation. Patient cohorts were defined based on severity of renal impairment per the National Kidney Foundation-Kidney Disease Outcomes Quality Initiative (NKD-KDOQI) guidelines based on the GFR value into normal &gt;90, mild 60–89, moderate 30–59, severe 15–29 and kidney failure &lt;15 ml/min/1.73m^2. Because there were only few patients in the last two groups (GFR of 15–29 =11 and GFR &lt;15 =13), they were combined into a single cohort of severe renal impairment (GFR &lt;30=24). We also defined patient cohorts based on a previously reported classification in MM wherein patients were divided based on severity of renal impairment into normal &gt;80, mild 50–80, moderate 30–49 and severe &lt;30 ml/min/1.73m^2. Survival curves and median survival were calculated by Kaplan-Meier method. Survival differences were calculated using a log-rank test. A 0.05 nominal significance level was used in all statistical testing. RESULTS: A total of 175 patients (M=88, F=87) with a median age 60 years (range 34–88) were evaluated. Majority of patients had stage III disease (64%), 57.1% had IgG myeloma and lytic bone disease present in 67.4% of the patients. Median values for SCr, serum calcium, blood urea nitrogen, serum albumin and hemoglobin were 1.1mg/dl (range-0.5–10.3), 9.5 mg/dl (range-7.5- 7.2), 18 mg/dl (range-5–107), 4.0 g/dl (range-2.2–5.5) and 11.5 g/dl (range-6.8–17.1) respectively. SCr &gt;2 mg/dl was seen in only 16% patients and 41.1% patients had GFR in the range of 60–89 ml/min/1.73m^2. Patients received an average of 2 treatments. Use of at least one of the novel agent was seen in 86.3% patients (Immunomodulatory drugs =130, Bortezomib = 97, Pegylated liposomal doxorubicin =65). Median survival for patients with SCr &lt;2.0 and SCr&gt;2.0 was 67.4 months (45.4 – 92.7 months) and 38.4 months (15.3 months – not reached) respectively. Median survival for patients with normal GFR and mild, moderate and severe renal impairment based on the NKD-KDOQI guidelines was 76.1 months (37.5 months – not reached), 55.32 months (34.8 months – not reached), 67.4 months (45.4 months – not reached) and 24.9 months (15.3 months – not reached) respectively. Median survival for patient cohorts defined based on a previously reported classification in MM was similar to that seen with the NKD-KDOQI classification. We noted no significant survival advantage of normal renal function over renally impaired patients (Figure 1 & 2) despite evaluations based either by using the traditional approach of SCr (p=0.15; log rank test) or by more sensitive renal function assessment by GFR (p=0.21; log rank test). CONCLUSIONS: We conclude that in MM patients the previously reported and commonly perceived adverse prognosis imparted by impaired renal function can no longer be validated and that routine incorporation of novel agents has overcome this adverse prognosis. These findings are consistent with the impact of novel agents reported in context with MM with aggressive molecular profiles. Figure 1: Kaplan-Meier curve for survival by serum creatinine (SCr) Figure 1:. Kaplan-Meier curve for survival by serum creatinine (SCr)" @default.
• W2583115655 created "2017-02-10" @default.
• W2583115655 creator A5006011014 @default.
• W2583115655 creator A5010286156 @default.
• W2583115655 creator A5013824370 @default.
• W2583115655 creator A5016601438 @default.
• W2583115655 creator A5042245087 @default.
• W2583115655 creator A5044589378 @default.
• W2583115655 creator A5050227848 @default.
• W2583115655 creator A5052202483 @default.
• W2583115655 creator A5063296413 @default.
• W2583115655 creator A5075486570 @default.
• W2583115655 creator A5086565464 @default.
• W2583115655 date "2008-11-16" @default.
• W2583115655 modified "2023-10-01" @default.
• W2583115655 title "Novel Agents Overcome the Adverse Prognosis Imparted by Compromised Renal Function in Patients with Multiple Myeloma" @default.
• W2583115655 doi "https://doi.org/10.1182/blood.v112.11.2726.2726" @default.
• W2583115655 hasPublicationYear "2008" @default.
• W2583115655 type Work @default.
• W2583115655 sameAs 2583115655 @default.
• W2583115655 citedByCount "2" @default.
• W2583115655 countsByYear W25831156552012 @default.
• W2583115655 countsByYear W25831156552013 @default.
• W2583115655 crossrefType "journal-article" @default.
• W2583115655 hasAuthorship W2583115655A5006011014 @default.
• W2583115655 hasAuthorship W2583115655A5010286156 @default.
• W2583115655 hasAuthorship W2583115655A5013824370 @default.
• W2583115655 hasAuthorship W2583115655A5016601438 @default.
• W2583115655 hasAuthorship W2583115655A5042245087 @default.
• W2583115655 hasAuthorship W2583115655A5044589378 @default.
• W2583115655 hasAuthorship W2583115655A5050227848 @default.
• W2583115655 hasAuthorship W2583115655A5052202483 @default.
• W2583115655 hasAuthorship W2583115655A5063296413 @default.
• W2583115655 hasAuthorship W2583115655A5075486570 @default.
• W2583115655 hasAuthorship W2583115655A5086565464 @default.
• W2583115655 hasConcept C126322002 @default.
• W2583115655 hasConcept C126894567 @default.
• W2583115655 hasConcept C159641895 @default.
• W2583115655 hasConcept C197934379 @default.
• W2583115655 hasConcept C2776063141 @default.
• W2583115655 hasConcept C2776364478 @default.
• W2583115655 hasConcept C2777478702 @default.
• W2583115655 hasConcept C2778653478 @default.
• W2583115655 hasConcept C2779609412 @default.
• W2583115655 hasConcept C2780091579 @default.
• W2583115655 hasConcept C2780306776 @default.
• W2583115655 hasConcept C71924100 @default.
• W2583115655 hasConcept C72563966 @default.
• W2583115655 hasConcept C90924648 @default.
• W2583115655 hasConceptScore W2583115655C126322002 @default.
• W2583115655 hasConceptScore W2583115655C126894567 @default.
• W2583115655 hasConceptScore W2583115655C159641895 @default.
• W2583115655 hasConceptScore W2583115655C197934379 @default.
• W2583115655 hasConceptScore W2583115655C2776063141 @default.
• W2583115655 hasConceptScore W2583115655C2776364478 @default.
• W2583115655 hasConceptScore W2583115655C2777478702 @default.
• W2583115655 hasConceptScore W2583115655C2778653478 @default.
• W2583115655 hasConceptScore W2583115655C2779609412 @default.
• W2583115655 hasConceptScore W2583115655C2780091579 @default.
• W2583115655 hasConceptScore W2583115655C2780306776 @default.
• W2583115655 hasConceptScore W2583115655C71924100 @default.
• W2583115655 hasConceptScore W2583115655C72563966 @default.
• W2583115655 hasConceptScore W2583115655C90924648 @default.
• W2583115655 hasLocation W25831156551 @default.
• W2583115655 hasOpenAccess W2583115655 @default.
• W2583115655 hasPrimaryLocation W25831156551 @default.
• W2583115655 hasRelatedWork W133743721 @default.
• W2583115655 hasRelatedWork W1583692985 @default.
• W2583115655 hasRelatedWork W1968833887 @default.
• W2583115655 hasRelatedWork W1986248422 @default.
• W2583115655 hasRelatedWork W1994249743 @default.
• W2583115655 hasRelatedWork W2004545479 @default.
• W2583115655 hasRelatedWork W2071129725 @default.
• W2583115655 hasRelatedWork W2100630464 @default.
• W2583115655 hasRelatedWork W2113494773 @default.
• W2583115655 hasRelatedWork W2148542306 @default.
• W2583115655 hasRelatedWork W2315087065 @default.
• W2583115655 hasRelatedWork W2385103445 @default.
• W2583115655 hasRelatedWork W2422581423 @default.
• W2583115655 hasRelatedWork W2558456064 @default.
• W2583115655 hasRelatedWork W2895039141 @default.
• W2583115655 hasRelatedWork W2953192301 @default.
• W2583115655 hasRelatedWork W3098483946 @default.
• W2583115655 hasRelatedWork W3163473741 @default.
• W2583115655 hasRelatedWork W3214251540 @default.
• W2583115655 hasRelatedWork W2777204865 @default.
• W2583115655 isParatext "false" @default.
• W2583115655 isRetracted "false" @default.
• W2583115655 magId "2583115655" @default.
• W2583115655 workType "article" @default.